ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 837.3 USD | +0.66% |
|
+2.73% | +43.64% |
| 06/06 | US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug | RE |
| 06/06 | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
| Sales 2024 * | 42.98B 3,587B | Sales 2025 * | 52.62B 4,391B | Capitalization | 749B 62,497B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 996B | Net income 2025 * | 16.55B 1,381B | EV / Sales 2024 * | 17.8 x |
| Net Debt 2024 * | 18.07B 1,508B | Net Debt 2025 * | 15B 1,252B | EV / Sales 2025 * | 14.5 x |
| P/E ratio 2024 * |
62.6
x | P/E ratio 2025 * |
45.1
x | Employees | 43,000 |
| Yield 2024 * |
0.62% | Yield 2025 * |
0.72% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +0.66% | ||
| 1 week | +3.17% | ||
| Current month | +2.07% | ||
| 1 month | +13.92% | ||
| 3 months | +7.68% | ||
| 6 months | +42.36% | ||
| Current year | +43.64% |
1 week
811.10
846.97
1 month
750.53846.97
Current year
579.05846.97
1 year
432.34846.97
3 years
201.83846.97
5 years
101.36846.97
10 years
58.50846.97
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/23/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 17 M€ | +8.17% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/24/06 | 837.3 | +0.66% | 2,108,488 |
| 05/24/05 | 831.8 | -0.10% | 2,169,003 |
| 04/24/04 | 832.6 | +0.16% | 1,748,288 |
| 03/24/03 | 831.3 | +1.33% | 2,537,239 |
| 31/24/31 | 820.3 | +0.65% | 4,472,119 |
Delayed Quote Nyse, June 07, 2024 at 01:30 am IST
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
837.3
USD
Average target price
852.5
USD
Spread / Average Target
+1.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.64% | 749B | |
| +39.42% | 605B | |
| -6.58% | 351B | |
| +19.72% | 328B | |
| +8.78% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.03% | 167B | |
| +6.13% | 165B | |
| +1.39% | 123B |
- Stock Market
- Equities
- LLY Stock
